InspireMD Reports Third Quarter 2025 Financial Results
Rhea-AI Summary
InspireMD (Nasdaq: NSPR) reported third quarter 2025 results and operational milestones on November 4, 2025. Total revenue rose 39% to $2.5M versus prior year, with U.S. revenue $497,000 and international $2.0M. The company initiated the U.S. commercial launch of CGuard Prime, recording over 100 U.S. procedures in leading hospitals. Gross profit was $864,000. Operating expenses increased to $13.9M (up 57%) driven by U.S. commercial hires and U.S. headquarters costs. Net loss was $12.7M, $0.17 per share versus $7.9M, $0.16 a year earlier. Cash and marketable securities totaled $63.4M, supported by $58M in gross proceeds raised in July. Management hosted a conference call on November 4, 2025 to discuss results.
Positive
- Revenue +39% to $2.5M in Q3 2025
- Initiated U.S. commercial launch of CGuard Prime
- Completed over 100 U.S. carotid procedures
- Cash and marketable securities $63.4M as of 9/30/2025
Negative
- Operating expenses +57% to $13.9M in Q3 2025
- Net loss widened to $12.7M, $0.17 per share in Q3 2025
- Financial income decreased 40% to $343,000 in Q3 2025
News Market Reaction 2 Alerts
On the day this news was published, NSPR declined 7.21%, reflecting a notable negative market reaction. Argus tracked a peak move of +11.0% during that session. Our momentum scanner triggered 2 alerts that day, indicating moderate trading interest and price volatility. This price movement removed approximately $7M from the company's valuation, bringing the market cap to $96M at that time.
Data tracked by StockTitan Argus on the day of publication.
Successful initial CGuard Prime U.S. commercial launch drives record quarterly revenue
MIAMI, Nov. 04, 2025 (GLOBE NEWSWIRE) -- InspireMD, Inc. (Nasdaq: NSPR) (“InspireMD” or the “Company”), developer of the CGuard® Prime carotid stent system for the prevention of stroke, today announced financial and operating results for the third quarter and nine months ended September 30, 2025.
Recent Business Highlights:
- Initiated U.S. commercial launch of the CGuard Prime carotid stent system
- Completed over 100 U.S. carotid procedures across leading hospitals
- Strengthened leadership team with the appointment of Peter A. Soukas, M.D., as Chief Medical Officer
- Appointed Dan Dearen to the Board of Directors as Audit Committee Chairman bringing valuable experience to InspireMD
Marvin Slosman, CEO of InspireMD, commented: “Our business demonstrated strong growth across all geographies in the third quarter of 2025. Over the last few months, our team executed our planned U.S. commercial launch of our CGuard Prime carotid stent system, which delivered measurable revenue in our initial commercial quarter in the United States. We continue to see strong demand for our solutions globally, validating our mission as we work to transform the carotid intervention market with a stent first approach."
"Further, with the addition of
Financial Results for the Third Quarter Ended September 30, 2025
For the third quarter of 2025, total revenue increased by
U.S. revenue for the third quarter was
Gross profit (revenue less cost of revenues) for the third quarter of 2025 was
Total operating expenses for the third quarter of 2025 were
Financial income, net for the third quarter of 2025 was
Net loss for the third quarter of 2025 was
As of September 30, 2025, cash and cash equivalents and marketable securities were
Conference Call and Webcast Details
Management will host a conference call at 8:30 am ET today, November 4th, to review financial results and provide an update on corporate developments. Following management’s formal remarks, there will be a question-and-answer session.
Tuesday, November 4th at 8:30 a.m. ET
| Domestic: | 1-800-579-2543 |
| International: | 1-785-424-1789 |
| Conference ID: | IMD3Q25 |
| Webcast: | Webcast Link – Click Here |
About InspireMD, Inc.
InspireMD seeks to utilize its proprietary MicroNet™ mesh technology to make its products the industry standard for carotid stenting by providing outstanding acute results and durable, stroke-free long-term outcomes. InspireMD’s common stock is quoted on Nasdaq under the ticker symbol NSPR. We routinely post information that may be important to investors on the Company’s website. For more information, please visit www.inspiremd.com.
Forward-looking Statements
This press release contains “forward-looking statements.” Forward-looking statements include, but are not limited to, statements regarding InspireMD or its management team’s expectations, hopes, beliefs, intentions or strategies regarding future events, future financial performance, strategies, expectations, competitive environment and regulation. Such statements may be preceded by the words “intends,” “may,” “will,” “plans,” “expects,” “anticipates,” “projects,” “predicts,” “estimates,” “aims,” “believes,” “hopes,” “potential”, “scheduled” or similar words. Forward-looking statements are not guarantees of future performance, are based on certain assumptions and are subject to various known and unknown risks and uncertainties, many of which are beyond the Company’s control, and cannot be predicted or quantified and consequently, actual results may differ materially from those expressed or implied by such forward-looking statements. Such risks and uncertainties include, without limitation, risks and uncertainties associated with the Company’s history of recurring losses and negative cash flows from operating activities, significant future commitments and the uncertainty regarding the adequacy of its liquidity to pursue its complete business objectives, and substantial doubt regarding its ability to continue as a going concern; the Company’s need to raise additional capital to meet its business requirements in the future and such capital raising may be costly or difficult to obtain and could dilute out stockholders’ ownership interests; the clinical development, commercialization and market acceptance of the Company’s products; whether the clinical trial results for the Company’s products will be predictive of real-world results; an inability to secure and maintain regulatory approvals for the sale of the Company’s products; negative clinical trial results or lengthy product delays in key markets; the Company’s ability to maintain compliance with the Nasdaq listing standards; the Company’s ability to generate significant revenues from its products; estimates of the Company’s expenses, future revenues, capital requirements and its needs for and ability to access sufficient additional financing, including any unexpected costs or delays in the ongoing commercial launch of its products; the Company’s dependence on a single manufacturing facility and its ability to comply with stringent manufacturing quality standards and to increase production as necessary; the risk that the data collected from the Company’s current and planned clinical trials may not be sufficient to demonstrate that its technology is an attractive alternative to other procedures and products; intense competition in the Company’s industry, with competitors having substantially greater financial, technological, research and development, regulatory and clinical, manufacturing, marketing and sales, distribution and personnel resources than it does; entry of new competitors and products and potential technological obsolescence of the Company’s products; inability to carry out research, development and commercialization plans; loss of a key customer or supplier; technical problems with the Company’s research and products and potential product liability claims; product malfunctions; price increases for supplies and components; whether access to the Company’s products is achieved in a commercially viable manner and whether its products receive adequate reimbursement by governmental and other third-party payers; the Company’s efforts to successfully obtain and maintain intellectual property protection covering its products, which may not be successful; adverse federal, state and local government regulation, in the United States, Europe or Israel and other foreign jurisdictions; the fact that the Company conducts business in multiple foreign jurisdictions, exposing it to foreign currency exchange rate fluctuations, logistical and communications challenges, burdens and costs of compliance with foreign laws and political and economic instability in each jurisdiction; security, political and economic instability in the Middle East that could harm the Company’s business, including due to the current security situation in Israel; current or future unfavorable economic and market conditions and adverse developments with respect to financial institutions and associated liquidity risk; and changes in tariffs, trade barriers, price and exchange controls and other regulatory requirements and the impact of such policies on the Company, its customers and suppliers, and the global economic environment. More detailed information about the Company and the risk factors that may affect the realization of forward-looking statements is set forth in the Company’s filings with the Securities and Exchange Commission (SEC), including the Company’s Annual Report on Form 10-K and its Quarterly Reports on Form 10-Q. Investors and security holders are urged to read these documents free of charge on the SEC’s web site at http://www.sec.gov. The Company assumes no obligation to publicly update or revise its forward-looking statements as a result of new information, future events or otherwise.
Investor Contacts:
Webb Campbell
Gilmartin Group LLC
Webb@gilmartinir.com
investor-relations@inspiremd.com
| CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS(1) (Unaudited) (U.S. dollars in thousands, except share and per share data) | ||||||||||||
| Three months ended September 30, | Nine months ended September 30, | |||||||||||
| 2025 | 2024 | 2025 | 2024 | |||||||||
| Revenues | ||||||||||||
| Cost of revenues | 1,659 | 1,396 | 4,361 | 4,023 | ||||||||
| Gross Profit | 864 | 414 | 1,469 | 1,037 | ||||||||
| Operating Expenses: | ||||||||||||
| Research and development | 3,635 | 3,915 | 11,528 | 9,941 | ||||||||
| Selling and marketing | 4,392 | 1,472 | 11,314 | 4,154 | ||||||||
| General and administrative | 5,888 | 3,489 | 16,157 | 11,078 | ||||||||
| Total operating expenses | 13,915 | 8,876 | 38,999 | 25,173 | ||||||||
| Loss from operations | (13,051 | ) | (8,462 | ) | (37,530 | ) | (24,136 | ) | ||||
| Financial income, net | 343 | 572 | 505 | 1,305 | ||||||||
| Net Loss | ) | ) | ) | ) | ||||||||
| Net loss per share – basic and diluted | ) | ) | ) | ) | ||||||||
| WEIGHTED AVERAGE NUMBER OF ORDINARY SHARES USED IN COMPUTING NET LOSS PER SHARE - basic and diluted | 73,466,501 | 48,369,412 | 58,245,368 | 39,413,004 | ||||||||
| CONDENSED CONSOLIDATED BALANCE SHEETS(1) (Unaudited) (U.S. dollars in thousands, except share and per share data) | ||||
| ASSETS | September 30, 2025 | December 31, 2024 | ||
| Current Assets: | ||||
| Cash and cash equivalents | ||||
| Marketable securities | - | 15,721 | ||
| Accounts receivable: | ||||
| Trade, net | 1,961 | 1,572 | ||
| Other | 475 | 682 | ||
| Prepaid expenses | 945 | 1,060 | ||
| Inventory | 3,607 | 2,570 | ||
| Total current assets | 70,391 | 40,521 | ||
| Non-current assets: | ||||
| Long term deposit | 438 | 426 | ||
| Property, plant and equipment, net | 3,403 | 2,371 | ||
| Operating lease right of use assets | 2,915 | 2,360 | ||
| Funds in respect of employee rights upon retirement | 1,325 | 1,129 | ||
| Total non-current assets | 8,081 | 6,286 | ||
| Total assets | ||||
| CONDENSED CONSOLIDATED BALANCE SHEETS(1) (Unaudited) (U.S. dollars in thousands, except share and per share data) | ||||||
| LIABILITIES AND EQUITY | September 30, 2025 | December 31, 2024 | ||||
| Current liabilities: | ||||||
| Accounts payable and accruals: | ||||||
| Trade | ||||||
| Other | 9,063 | 6,424 | ||||
| Total current liabilities | 10,816 | 7,678 | ||||
| Long-term liabilities: | ||||||
| Operating lease liabilities net of current maturities | 2,367 | 1,796 | ||||
| Liability for employee rights upon retirement and others | 1,175 | 1,247 | ||||
| Total long-term liabilities | 3,542 | 3,043 | ||||
| Total liabilities | ||||||
| Equity: | ||||||
| Common stock, par value shares authorized at September 30, 2025, and December 31, 2024; 41,919,141 and 26,611,033 shares issued and outstanding on September 30, 2025, and December 31, 2024, respectively | 4 | 3 | ||||
| Preferred C shares, par value 1,172,000 shares authorized at September 30, 2025, and December 31, 2024; 1,718 shares issued and outstanding at September 30, 2025, and December 31, 2024, respectively | * | * | ||||
| Additional paid-in capital | 354,641 | 289,589 | ||||
| Accumulated deficit | (290,531 | ) | (253,506 | ) | ||
| Total equity | 64,114 | 36,086 | ||||
| Total liabilities and equity | ||||||
(1) All September 30, 2025, financial information is derived from the Company’s 2025 unaudited financial statements, as disclosed in the Company’s Quarterly Report on Form 10-Q, filed with the Securities and Exchange Commission on November 10, 2025. All December 31, 2024, financial information is derived from the Company’s 2024 audited financial statements as disclosed in the Company’s Annual Report on Form 10-K, for the twelve months ended December 31, 2024, filed with the Securities and Exchange Commission on March 12, 2025.
FAQ
What were InspireMD (NSPR) Q3 2025 total revenues and growth?
How much U.S. revenue did InspireMD (NSPR) record in Q3 2025?
What was InspireMD's (NSPR) Q3 2025 net loss per share and total loss?
How much cash did InspireMD (NSPR) have after its July financing?
What commercial progress did InspireMD (NSPR) report for CGuard Prime in 2025?
Why did InspireMD (NSPR) operating expenses rise in Q3 2025?
